Affiliation:
1. School of Pharmacy, Anhui Medical University, Hefei 230032, China
2. State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, China
Abstract
The Lassa virus (LASV) causes Lassa fever, a highly infectious and lethal agent of acute viral hemorrhagic fever. At present, there are still no effective treatments available, creating an urgent need to develop novel therapeutics. Some benzimidazole compounds targeting the arenavirus envelope glycoprotein complex (GPC) are promising inhibitors of LASV. In this study, we synthesized two series of LASV inhibitors based on the benzimidazole structure. Lentiviral pseudotypes bearing the LASV GPC were established to identify virus entry inhibitors. Surface plasmon resonance (SPR) was further used to verify the binding activities of the potential compounds. Compounds 7d−Z, 7h−Z, 13c, 13d, and 13f showed relatively excellent antiviral activities with IC50 values ranging from 7.58 to 15.46 nM and their SI values above 1251. These five representative compounds exhibited stronger binding affinity with low equilibrium dissociation constants (KD < 8.25 × 10−7 M) in SPR study. The compound 7h−Z displayed the most potent antiviral activity (IC50 = 7.58 nM) with a relatively high SI value (2496), which could be further studied as a lead compound. The structure–activity relationship indicated that the compounds with lipophilic and spatially larger substituents might possess higher antiviral activity and a much larger safety margin. This study will provide some good guidance for the development of highly active compounds with a novel skeleton against LASV.
Funder
State Key Laboratory of Pathogen and Biosecurity
Subject
Chemistry (miscellaneous),Analytical Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Molecular Medicine,Drug Discovery,Pharmaceutical Science
Reference45 articles.
1. (2022, December 25). WHO Health Topics (Lassa Fever) Introduction to Lassa Fever. Available online: https://www.who.int/health-topics/lassa-fever/.
2. Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection;Brouwer;Cell Host Microbe,2022
3. Early-onset sensorineural hearing loss in Lassa fever;Ibekwe;Eur. Arch. Otorhinolaryngol.,2011
4. Acute sensorineural deafness in Lassa fever;Cummins;Jama,1990
5. Historical Lassa fever reports and 30-year clinical update;Macher;Emerg. Infect. Dis.,2006
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献